Skip to content

Evaluation of ejection fraction based on four-dimensional automatic volume quantification and spot tracking technology to preserve left ventricular function in patients with heart failure

Evaluation of ejection fraction based on 4D Auto VQ and STI technology to preserve left ventricular function in patients with heart failure

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045687
Enrollment
Unknown
Registered
2021-04-23
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with preserved ejection fraction

Interventions

Gold Standard:Brain natriuretic peptide, magnetic resonance, nuclide.
Auto&#32
VQ&#32
and&#32
STI&#32
technology

Sponsors

People's Hospital of Shapingba District, Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 100 Years

Inclusion criteria

Inclusion criteria: HFPEF group: According to the HFpEF diagnostic criteria of the 2018 Chinese Heart Failure Diagnosis and Treatment Guidelines, 100-120 patients with HFpEF from May 2022 to August 2023 were collected: 1.There are signs or symptoms of congestive heart failure: pulmonary rales, pulmonary edema, ankle swelling, hepatomegaly, difficulty breathing during exercise or resting, fatigue, etc.; 2.Left ventricular systolic function: LVEF>50%; 3.Increased natriuretic peptide: B-type natriuretic peptide (BNP)>35ng/L and/or N-terminal B-type natriuretic peptide (NT-proBNP)>125ng/L. 4.Related structural heart disease (LV hypertrophy or LA enlargement), or abnormal diastolic function. Abnormal diastolic function of the left ventricle: E/e'>15; if 15>E/e'>8, also need to include [a. Mitral valve blood flow spectrum (E/A280ms) or pulmonary venous blood Flow spectrum (Ard-Ad>30ms); b.LAVI>40ml/m2, LVMI>149d/m2 (male) />122g/m2 (female)]. Control group: 100-120 healthy people were screened according to the age and gender of the enrolled patients.

Exclusion criteria

Exclusion criteria: 1. Primary pulmonary hypertension; 2. Severe lung disease; 3. Unstable coronary artery disease, acute coronary syndrome; 4. Congenital heart disease; 5. Persistent arrhythmia; 6. Heart valve disease, severe heart valve calcification after heart valve surgery; 7. Severe kidney disease; 8. Severe liver disease; 9. Pacemaker surgery; 10. Pericardial disease.

Design outcomes

Primary

MeasureTime frame
Left anterior descending branch;Left ventricular end diastolic diameter;Left ventricular end systolic diameter;Left ventricular end-diastolic volume;Left ventricular end systolic volume;Left ventricular ejection fraction;Peak velocity in early diastole;Peak velocity in late diastole;TR peak flow rate of tricuspid regurgitation;Early diastolic velocity of mitral valve annulus;receive operating characteristic, ROC;Consistency;

Countries

china

Contacts

Public ContactYang Xi

People's Hospital of Shapingba District, Chongqing

yangxi_210@126.com+86 13228685396

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026